![Andrew Robell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Robell
Corporate Officer/Principal chez Phase 2 Discovery, Inc.
Postes actifs de Andrew Robell
Sociétés | Poste | Début | Fin |
---|---|---|---|
Phase 2 Discovery, Inc.
![]() Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Corporate Officer/Principal | - | - |
Historique de carrière de Andrew Robell
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Phase 2 Discovery, Inc.
![]() Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Health Technology |
- Bourse
- Insiders
- Andrew Robell
- Expérience